Between March 2020 and February 2022, vaccine-maker Emergent BioSolutions was forced to discard or destroy up to 400 million doses' worth of the key component of both Johnson & Johnson's and AstraZeneca's coronavirus vaccine due to quality-control issues, according to a congressional report published Tuesday -- a figure that reflects more than five times what was previously disclosed by the beleaguered firm.